These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 30396186)
1. BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens. Lee PJ; Dennis K; Madan R; Fan F Acta Cytol; 2019; 63(1):10-16. PubMed ID: 30396186 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250 [TBL] [Abstract][Full Text] [Related]
3. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. Yaman B; Kandiloğlu G; Akalin T Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683 [TBL] [Abstract][Full Text] [Related]
4. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes. Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422 [TBL] [Abstract][Full Text] [Related]
5. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods. O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234 [TBL] [Abstract][Full Text] [Related]
6. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and clinical outcomes associated with TP53 and BRAF Kim DW; Haydu LE; Joon AY; Bassett RL; Siroy AE; Tetzlaff MT; Routbort MJ; Amaria RN; Wargo JA; McQuade JL; Kemnade J; Hwu P; Woodman SE; Roszik J; Kim KB; Gershenwald JE; Lazar AJ; Davies MA Cancer; 2017 Apr; 123(8):1372-1381. PubMed ID: 27911979 [TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
9. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma. Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765 [TBL] [Abstract][Full Text] [Related]
10. Testing for Le Flahec G; Briolais M; Guibourg B; Lemasson G; Grippari JL; Ledé F; Marcorelles P; Uguen A J Clin Pathol; 2020 Feb; 73(2):116-119. PubMed ID: 31506288 [TBL] [Abstract][Full Text] [Related]
11. Is it good or bad to find a BRAF mutation? Flaherty KT J Clin Oncol; 2011 Apr; 29(10):1229-30. PubMed ID: 21343552 [No Abstract] [Full Text] [Related]
12. BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis. Maxwell R; Garzon-Muvdi T; Lipson EJ; Sharfman WH; Bettegowda C; Redmond KJ; Kleinberg LR; Ye X; Lim M Int J Cancer; 2017 Jun; 140(12):2716-2727. PubMed ID: 27342756 [TBL] [Abstract][Full Text] [Related]